AUAUniversity

Crossfire In Urology - Robotic Reconstruction by American Urological Association

At the conclusion of this activity, participants will be able to:

1. Discuss the evolving landscape of adjuvant therapy for the treatment of advanced bladder cancer and analyze the risks and benefits of the new and emerging treatment options.

2.Describe the mechanism of action and associated side effects of the new adjuvant therapy.

3. Differentiate the roles between the urologist and medical oncologist in the care of patients with bladder cancer.

4. Discuss the opportunities for the coordination of care between the urologists and medical oncologists.

This educational series is supported by an independent educational grant from:

Bristol Myers Squibb

CME available: https://auau.auanet.org/node/30870

AUA Guidelines Case - Based Panel Stress Urinary Incontinence by American Urological Association

Panel Discussion - Peyronie's Disease Management by American Urological Association

Pain Management In Urologic Surgery by American Urological Association

Bulbar Urethral Strictures 101 - A Review Of The Guidelines And Basic Management Options by American Urological Association

Learning Objective: At the conclusion of this continuing medical education activity, the participant will be able to select different strategies for ureteroscopic renal stone surgery, determine how laser parameter selection can improve lithotripsy efficiency and identify the important safety considerations to optimize patient outcomes.

At the conclusion of this activity, participants will be able to:

1. Explain the sequencing of novel therapies and be able to identify patient progression of disease.

2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29811

At the conclusion of this activity, participants will be able to:

1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.

2. Explain best practices in MIBC and NMIBC patient selection for various treatment options.

3. Facilitate discussions with patients and caregivers regarding their treatment options.

This educational series is supported by independent educational grants from:

• Astellas

• AstraZeneca

• Bristol Myers Squibb

• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

• Merck

• Pfizer, Inc

• Sanofi Genzyme

• UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29836

Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)

Presented by Leonard Gomella, MD and Joshua Lang, MD

This educational activity is supported by independent educational grants from:

AbbVie

Astellas

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc.

CME Available: https://auau.auanet.org/node/30124